Gelesis Holdings, Inc. (GLS)

NYSE: GLS · IEX Real-Time Price · USD
6.26 -0.37 (-5.51%)
Jan 25, 2022 9:47 AM EST - Market open
Market Cap13.52M
Revenue (ttm)10.49M
Net Income (ttm)-232.42M
Shares Out2.16M
EPS (ttm)-110.23
PE Ration/a
Forward PEn/a
Ex-Dividend Daten/a
Previous Close6.62
Day's Range6.24 - 6.33
52-Week Range4.53 - 7.28
Price Targetn/a
Earnings Daten/a

About GLS

Gelesis Holdings Inc., a biotherapeutics company, developing a novel category of treatments for weight management and gut related chronic diseases. It develops a mechanobiology technology platform to treat obesity and other chronic diseases related to the GI pathway. The company also provides PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, it offers a product for obesity and overweight and a pipeline with potential therapies for non-alcoholic fatty liver disease/non-alcoholic steatohepati...

Stock ExchangeNYSE
Ticker SymbolGLS
Full Company Profile

Financial Performance

Financial Statements


Gelesis, Maker Of Weight Loss Pill, Concludes SPAC Deal; Trading Kickstarts Today

PureTech Health plc (NASDAQ: PRTC) founded entity Gelesis Inc, maker of weight management aid, has completed its business combination with Capstar Special Purpose Acquisition Corp (NYSE: CPSR).  The pub...

1 week ago - Benzinga

Gelesis®, the Maker of Plenity® for Weight Management, Will Debut as a Publicly Traded Company Following the Closing ...

BOSTON & AUSTIN, Texas--(BUSINESS WIRE)--Gelesis, the maker of Plenity®, an FDA-cleared weight management approach, announced today the completion of its business combination with Capstar Special Purpos...

1 week ago - Business Wire

Gelesis Adds Inogen Co-Founder and Former CFO Ali Bauerlein to Board of Directors and Audit Committee

BOSTON--(BUSINESS WIRE)--Gelesis, a biotherapeutics company focused on excess weight and metabolic disorders and the maker of Plenity®, announced the appointment of senior financial executive Ali Bauerl...

2 weeks ago - Business Wire

Have Your Cake and Eat It Too: Plenity® Creates Edible Dessert Billboard to Challenge Overly Restrictive Dieting Assu...

BOSTON--(BUSINESS WIRE)-- #PlenityBillboardBites--Gelesis, the maker of Plenity®, an FDA-cleared weight management approach, has created an edible billboard in New York City's Astor Place to challenge t...

1 month ago - Business Wire

Gelesis' FDA-Cleared Weight Management Approach, Plenity®, Now Broadly Available and Leading Nutrition Authority Joy ...

BOSTON--(BUSINESS WIRE)--Gelesis, a consumer-focused biotherapeutics company, is proud to announce Plenity®, an FDA cleared weight management approach, is now broadly available across the United States ...

1 month ago - Business Wire

PureTech Founded Entity Gelesis Receives $30 Million Plenity® Order from Ro

BOSTON--(BUSINESS WIRE)--PureTech announces that its Founded Entity, Gelesis, received a $30 million fully paid pre-order for Plenity® from Ro.

Other symbols:PRTC
2 months ago - Business Wire

Gelesis Receives $30 Million Plenity Order from Ro

BOSTON--(BUSINESS WIRE)--Gelesis announced today that leading U.S. direct-to-patient healthcare company Ro has placed a $30 million fully paid pre-order for the company's first commercial product for we...

2 months ago - Business Wire

Capstar Special Purpose Acquisition Corp. and Gelesis Revise Transaction Terms

AUSTIN, Texas--(BUSINESS WIRE)--Capstar Special Purpose Acquisition Corp. (NYSE: CPSR) (“Capstar”), a special purpose acquisition company, announced that the valuation of its previously announced transa...

2 months ago - Business Wire

Nature's Scientific Reports Features Gelesis' Novel and Foundational Biomimetic Platform for Treating Obesity and Con...

BOSTON--(BUSINESS WIRE)--Gelesis, a consumer-focused biotherapeutics company and the maker of Plenity®, announced today a publication in Nature's Scientific Reports describing the genesis of the underly...

2 months ago - Business Wire

Two Senior Scientific Leaders at Gelesis Awarded Top Industry Honors

BOSTON--(BUSINESS WIRE)--Gelesis, a consumer-focused biotherapeutics company and the maker of Plenity®, announced that two senior leaders in the company, Elaine Chiquette, Pharm.D., and Elizabeth Pash, ...

2 months ago - Business Wire

FDA-Approved Weight Loss Drug Plenity's Parent Announces SPAC Deal: What Investors Should Know

A SPAC deal announced Monday could help accelerate the manufacturing of a promising weight loss drug targeting over 150 million people.  The SPAC Deal: Gelesis announced a SPAC merger with Capstar Speci...

6 months ago - Benzinga

Gelesis, a Consumer-Focused Biotherapeutics Company and the Maker of Plenity®, to Become a Publicly Traded Company vi...

BOSTON & AUSTIN, Texas--(BUSINESS WIRE)--Gelesis, Inc. (“Gelesis” or the “Company”), a biotherapeutics company advancing biomimetic superabsorbent hydrogels to treat excess weight and metabolic disorder...

6 months ago - Business Wire